March 22, 2018 / 6:44 AM / in 5 months

BRIEF-Chiome Bioscience says execution of collaborative development license and exclusive option agreement for anti-Semaphorin 3A antibody

March 22(Reuters) - Chiome Bioscience Inc

* Says it has executed a collaborative development license and exclusive option agreement with SemaThera Inc. for anti-Semaphorin 3A antibody for the development of therapeutics and diagnostics in Diabetic Macular Edema (DME) and other diabetic complications including non-ocular diseases

Source text in Japanese:goo.gl/DkP1Px

Further company coverage: (Beijing Headline News)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below